- Insurers, patients and other payers are pushing back against what they believes is the exorbitant fee that Gilead (GILD) is charging for its new hepatitis C drug Sovaldi.
- Previously: Pfizer lung-cancer drug fails in two Phase III studies
- The pill costs $1,000 a pop, or $84,000 for a 12-week treatment vs $66,000 for the current standard of care.
- The likes of Express Scripts (ESRX), Catamaran (CTRX), Aetna (AET) and CVS Caremark (CVS) are among those who are looking to pit similar treatments against each other, declining to provide coverage for some, and refusing to pay a premium based on one therapy being more convenient than another.
This was corrected on 01/27/2014 at 07:51 AM.
From other sites
at 4-traders.com (Mar 24, 2015)
at MarketRealist.com (Mar 24, 2015)
at Nasdaq.com (Mar 17, 2015)
at Zacks.com (Mar 6, 2015)
at Benzinga.com (Feb 27, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs